The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
The inspection concluded with zero Form 483 observations
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
Changhua site meets international regulatory standards for global medical applications
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
Subscribe To Our Newsletter & Stay Updated
